Veryan Medical

Board Announcement – Appointment of new CEO

Jason Marsh — Thu, 01 Sep 2022 09:07:56 +0000

The Board of Veryan Holdings Ltd announces that, following 11 years of service, including 8 years as COO and 3 years as CEO, Nick Yeo has decided to leave Veryan to pursue new professional and personal goals. Christian Bell, Chairman of the Veryan Board said, “Nick has made a tremendous contribution to Veryan during the clinical development and commercialisation of the BioMimics 3D Vascular Stent System and the integration with Otsuka Medical Devices Co., Ltd. following its acquisition of Veryan in 2018. The management of Otsuka Medical Devices Co., Ltd. and the Veryan board wish to thank Nick for his unparalleled contribution and wish him all the best for his future.”Chas Taylor, who led Veryan’s business from 2007 to 2019 and who has been serving as a non-executive director since stepping down as CEO, has agreed to assume the role of Interim CEO and will work with the Veryan Board and its experienced Executive Team to deliver on its next phase of development.

The post Board Announcement – Appointment of new CEO appeared first on Veryan Medical.

Board Announcement – Appointment of new CEO

Jason Marsh — Thu, 01 Sep 2022 08:32:22 +0000

The post Board Announcement – Appointment of new CEO appeared first on Veryan Medical.

MIMICS-2 3-year data released

Jason Marsh — Fri, 18 Sep 2020 10:20:42 +0000

Learn How To Boost Your Revenue

With Avada Business Coach

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla id quam vitae sapien congue ultrices. Pellentesque tincidunt nunc libero, sit amet placerat mi maximus sit amet. Aliquam erat volutpat. Integer suscipit congue fermentum. Fusce tempus viverra auctor. Fusce sit amet faucibus libero. Phasellus maximus, felis nec eleifend maximus, ex dolor aliquet tellus, quis porttitor nunc quam eget nibh. Nulla facilisi. Nam fringilla interdum ligula, vitae viverra nunc lobortis ac.

Sed luctus convallis nunc, vel molestie massa sollicitudin eu. Phasellus dictum, ex a ultrices vulputate, mi tellus viverra ex, vitae porta lacus justo sit amet libero. Nam eget odio mollis sem bibendum fermentum non nec dui. Quisque ultrices dolor lacus, vitae gravida neque consectetur in. Morbi risus risus, ullamcorper non convallis nec, elementum ut ante. Cras placerat eu metus convallis fringilla. Donec in justo nisi. Praesent placerat dui quis nulla lobortis fringilla. Curabitur varius blandit tellus, ac mattis nisl accumsan vel. Suspendisse eleifend pellentesque gravida. Curabitur vitae felis tortor. Donec ornare fringilla nibh ac mattis. Donec orci nunc, aliquet nec pretium eget, convallis et felis. Maecenas congue lectus nec tempor accumsan.

Nullam faucibus sed leo eu porta. Nunc vestibulum urna a hendrerit vestibulum. Sed mattis facilisis euismod. Mauris mattis eros sit amet nunc bibendum fermentum. Suspendisse diam risus, lacinia ac eleifend sollicitudin, fringilla sit amet augue. Integer lacinia ipsum nec dignissim dignissim. Suspendisse potenti. Integer malesuada sapien non consequat tincidunt. Donec euismod maximus velit in commodo. Mauris ut nulla turpis. Morbi consectetur venenatis malesuada. Praesent vestibulum cursus lacinia.

The post MIMICS-2 3-year data released appeared first on Veryan Medical.

Veryan & Otsuka

Jason Marsh — Fri, 18 Sep 2020 10:07:06 +0000

Veryan people

Where we’ve come from

Veryan was founded in 2005 as the result of a technology spin out from Imperial College, London, based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering Imperial College) on the link between vessel geometry, blood flow mechanics and vascular disease.

Heritage

Veryan used its understanding of swirling flow and its expertise in research and development to design, develop and patent the highly innovative three-dimensional (3D), nitinol (nickel-titanium alloy) BioMimics 3D Vascular Stent System.

Part of Otsuka Medical Devices

Veryan became an Otsuka Medical Devices company in 2018.

With our long track record of R&D, clinical, regulatory and commercial achievements and the support and endorsement of notable, international KOLs, we bring real, practical, unique solutions to challenges that physicians face daily; delivering intelligent design and improved clinical outcomes.

Big venture companies

Otsuka is a big venture company, one that takes risks and focuses on unmet clinical needs to develop new and better therapies. Otsuka harnesses the extraordinary creative and innovative abilities of its people to solve problems differently and to persevere until they find answers. Otsuka encourages its people to follow their dreams, as turning dreams into reality is at the heart of everything in life.

Veryan, an Otsuka Medical Devices company

Otsuka established Otsuka Medical Devices in 2011 as a focused strategic company with the vision to create a game-changing approach to medical devices combining pharmaceutical expertise with intelligent design solutions. Otsuka Medical Devices and Veryan cooperate closely with a shared culture based on ambition, innovation, calculated risk taking, and unconventional thinking.

Explore Otsuka’s unique culture

In Tokushima, Otsuka Pharmaceutical’s birthplace in Japan, three symbols illustrate how Otsuka likes to think differently and avoid stereotypes.

Click the images below to discover what these symbols represent.

Visit Otsuka’s U.S. site for more information on the company culture.

An extraordinary curved cedar tree that has another cedar tree lying on top of it in a way that does not look possible, yet the whole structure maintains a perfect balance. The aim of this structure is to convey a message about breaking down stereotypes and to change perceptions of what is and isn’t possible.

Veryan & Otsuka

Who we are Where we're going Our innovative approach Careers Veryan Board Executive Team A day in the life - Design Assurance Team Where we've come from Veryan was founded ...

The Right Tech

Learn How To Boost Your Revenue With Avada Business Coach Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla id quam vitae sapien congue ultrices. Pellentesque tincidunt nunc libero, sit amet placerat ...

Working Environment

The post Veryan & Otsuka appeared first on Veryan Medical.

The Right Tech

Jason Marsh — Fri, 18 Sep 2020 09:55:42 +0000

Learn How To Boost Your Revenue

With Avada Business Coach

The post The Right Tech appeared first on Veryan Medical.

Working Environment

Jason Marsh — Fri, 18 Sep 2020 09:47:52 +0000

Learn How To Boost Your Revenue

With Avada Business Coach

The post Working Environment appeared first on Veryan Medical.

Business Strategy

Jason Marsh — Fri, 18 Sep 2020 09:40:35 +0000

Learn How To Boost Your Revenue

With Avada Business Coach

The post Business Strategy appeared first on Veryan Medical.

Making Headlines

Jason Marsh — Fri, 18 Sep 2020 09:15:23 +0000

Learn How To Boost Your Revenue

With Avada Business Coach

The post Making Headlines appeared first on Veryan Medical.

BioMimics 3D US launch

Jason Marsh — Wed, 02 Sep 2020 07:45:39 +0000

01 September 2020Nick Yeo, Veryan’s CEO commented: “Launching BioMimics 3D in the US marks a significant landmark for Veryan. In preparation for this important commercial step, we have recruited a senior sales team, highly experienced in percutaneous vascular intervention, led by Joe DeJohn, Veryan’s US-based, Chief Commercial Officer. I am confident that in building our commercial organisation on such strong networked foundations, supported by a major, real-world Registry study that we expect to launch in US next Quarter, we will quickly establish BioMimics 3D as the go-to stent for femoropopliteal intervention in the US.”The benefits of the BioMimics 3D stent design have been well established in the MIMICS clinical research program, enrolling more than 1750 patients worldwide. The most recent findings are the 3-year follow-up data from the MIMICS-2 study which were presented by Professor Thomas Zeller (University Heart Center Freiburg, Bad Krozingen, Germany) at CX 2020 Live in June. MIMICS-2 is a prospective, single-arm, multicentre study that evaluated the safety and effectiveness of the BioMimics 3D Vascular Stent System in the treatment of patients with symptomatic atherosclerotic disease of the femoropopliteal artery.Professor Zeller reported at CX 2020, that the 3-year freedom from clinically-driven target lesion revascularization (CDTLR) for BioMimics 3D was 81%; a result that is comparable to outcomes with drug-coated and latest generation bare nitinol stents, despite treating more challenging lesions and without the need for lesion preparation. BioMimics 3D thus provides increased procedural simplicity for physicians, and durable, long-term clinical outcome benefit for patients.1Professor Zeller commented: “I have been using BioMimics 3D routinely in my clinical practice for several years and I am delighted that my US colleagues will also now have this opportunity. The 3-dimensional helical shape of the stent promotes swirling blood flow, a protective phenomenon that occurs naturally in the vasculature, but which can be disrupted, predisposing to atherosclerotic disease and neointimal formation at the site of vascular intervention that can lead to restenosis and the need for re-intervention.2 Data from the MIMICS Clinical Program, including those from our MIMICS Randomized Clinical Trial, comparing the performance of the helical-shaped BioMimics 3D to that of a straight stent, support the clinical benefits of Veryan’s unique stent design that promotes swirling blood flow and improves biomechanical performance in the stented segment.3 I’m sure that the stent will not just be a valuable addition to my US colleagues’ treatment options, but for many will become their primary therapy for femoropopliteal disease.”BioMimics 3D Vascular Stent SystemThe BioMimics 3D stent has a unique 3-dimensional helical shape, designed to impart natural curvature to the diseased femoropopliteal artery, promoting swirling flow and elevating wall shear, which has been proven to have a protective effect on the endothelium.2 The helical shape of the BioMimics 3D stent is also designed to facilitate shortening of the stented segment during knee flexion and mitigate the risk of stented segment compression causing localised strains that in a straight stent may lead to stent fracture and chronic vascular injury.4,5About Veryan MedicalVeryan became an Otsuka Medical Devices company in December 2018 and applies design intelligence to create medical devices for vascular intervention that improve patient care through a combination of imagination, intuition and innovation. Veryan has offices in Horsham, UK, and Galway, Ireland, the location of the Veryan Innovation Centre that houses the Company’s R&D activities. Veryan has direct sales teams in Germany and the US and has appointed distributors in other markets. The BioMimics 3D Vascular Stent System has Premarket Approval in US and Japan and CE Mark approval in Europe. BioMimics 3D and Swirling Flow are registered trademarks of Veryan Medical Ltd. For more information: Veryan Medical Ltd. www.veryanmed.comVanessa Lee, Marketing Director [email protected] References1. Zeller T. Oral Presentation CX Live 20202. Caro et al. 2013 J R Soc Interface 10: 201305783. Zeller T. et al; Circ Cardiovasc Interv. 2016;94. BH Smouse et al, Endovasc. Today, vol 4, no. 6, pp. 60-66, 20055. Scheinert D et al, J Am Coll Cardiol 2005;45:312-5

The post BioMimics 3D US launch appeared first on Veryan Medical.

BioMimics 3D US launch

Jason Marsh — Wed, 02 Sep 2020 07:26:07 +0000

The post BioMimics 3D US launch appeared first on Veryan Medical.

Veryan Medical

Board Announcement – Appointment of new CEO

Board Announcement – Appointment of new CEO

MIMICS-2 3-year data released

With Avada Business Coach

Veryan & Otsuka

Veryan people

Heritage

Part of Otsuka Medical Devices

Big venture companies

Veryan, an Otsuka Medical Devices company

Explore Otsuka’s unique culture

More From Veryan

Veryan & Otsuka

The Right Tech

Working Environment

The Right Tech

With Avada Business Coach

Working Environment

With Avada Business Coach

Business Strategy

With Avada Business Coach

Making Headlines

With Avada Business Coach

BioMimics 3D US launch

BioMimics 3D US launch